Nan Zhu

Nan Zhu, Ph.D.

Associate Professor

Bio

Nan Zhu, Ph.D. is an associate professor at J. Craig Venter Institute in the synthetic biology group. Prior to joining JCVI she was an Investigator at Versiti Blood Reach Institute in the Stem Cell and Hematopoiesis Program and held a joint appointment as an assistant professor at the Medical College of Wisconsin in the Department of Cell Biology, Neurobiology and Anatomy (CBNA).

At Versiti, her laboratory studied the epigenetic regulation of stem cells and how dysregulation of these pathways contributes to the development of leukemia. Epigenetic mechanisms play an important role in maintaining tissue-specific gene expression patterns and are essential for normal development processes. In leukemia, cancer cells often harbor multiple genetic mutations that cause them to divide in an uncontrolled manner, leading to tumor formation and growth. Mutations in epigenetic regulators are frequently found in leukemia, highlighting their importance in malignancy.

At JCVI, Dr. Zhu’s research will build upon this body of work. Her lab will be focused on understanding the epigenetic regulation of normal and malignant hematopoiesis (the process by which the body makes blood cells), especially as it relates to Acute Myeloid Leukemia, the most aggressive form of the disease.

Dr. Zhu earned a BS in biochemistry from Nanjing University in China and a Ph.D. in biology from Boston University. Her post-graduate training includes research fellowships at Brigham and Women’s Hospital and Children’s Hospital Boston (both teaching hospitals of Harvard Medical School).

Publications

Publications

ACS medicinal chemistry letters. 2025-10-09; 16.10: 1955-1962.

Polybromo‑1 Bromodomain Inhibitor Selectivity Is Mediated by a Unique Ligand-Binding Pocket

Nuñez R, Bursch KL, Makowski SJ, Xue M, Cozzolino KA, Shishodia S, Keyes RF, Zhu N, Smith BC
PMID: 41089488

Blood. 2023-04-06; 141.14: 1653-1655.

Silencing with SAFB: a new role for HOXA9 in AML

Deshpande AJ, Zhu N
PMID: 37022737

Frontiers in cell and developmental biology. 2022-05-26; 10.917125.

The Role of DOT1L in Normal and Malignant Hematopoiesis

Arnold O, Barbosa K, Deshpande AJ, Zhu N
PMID: 35712672

Leukemia. 2022-04-01; 36.4: 946-955.

Differential roles of BAF and PBAF subunits, Arid1b and Arid2, in MLL-AF9 leukemogenesis

Bluemn T, Schmitz J, Zheng Y, Burns R, Zheng S, DeJong J, Christiansen L, Arnold O, Izaguirre-Carbonell J, Wang D, Deshpande AJ, Zhu N
PMID: 35022500

Scientific reports. 2021-03-31; 11.1: 7288.

DOT1L inhibitors block abnormal self-renewal induced by cohesin loss

Heimbruch KE, Fisher JB, Stelloh CT, Phillips E, Reimer MH, Wargolet AJ, Meyer AE, Pulakanti K, Viny AD, Loppnow JJ, Levine RL, Pulikkan JA, Zhu N, Rao S
PMID: 33790356

Experimental hematology. 2021-02-01; 94.37-46.

Arid2 regulates hematopoietic stem cell differentiation in normal hematopoiesis

Bluemn T, Schmitz J, Chen Y, Zheng Y, Zhang Y, Zheng S, Burns R, DeJong J, Christiansen L, Izaguirre-Carbonell J, Wang D, Zhu N
PMID: 33346030

Experimental hematology. 2020-05-11; 85.57-69.

Epigenetic regulation of protein translation in KMT2A-rearranged AML

Lenard A, Xie HM, Pastuer T, Shank T, Libbrecht C, Kingsley M, Riedel SS, Yuan ZF, Zhu N, Neff T, Bernt KM
PMID: 32437908

Nature communications. 2019-09-27; 10.1: 4415.

CXCR5+PD-1+ follicular helper CD8 T cells control B cell tolerance

Chen Y, Yu M, Zheng Y, Fu G, Xin G, Zhu W, Luo L, Burns R, Li QZ, Dent AL, Zhu N, Cui W, Malherbe L, Wen R, Wang D
PMID: 31562329

Blood advances. 2019-05-14; 3.9: 1499-1511.

Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia

Izaguirre-Carbonell J, Christiansen L, Burns R, Schmitz J, Li C, Mokry RL, Bluemn T, Zheng Y, Shen J, Carlson KS, Rao S, Wang D, Zhu N
PMID: 31076406

The Journal of clinical investigation. 2016-03-01; 126.3: 997-1011.

MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C

Zhu N, Chen M, Eng R, DeJong J, Sinha AU, Rahnamay NF, Koche R, Al-Shahrour F, Minehart JC, Chen CW, Deshpande AJ, Xu H, Chu SH, Ebert BL, Roeder RG, Armstrong SA
PMID: 26878175

Cancer cell. 2011-07-12; 20.1: 66-78.

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L

Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA
PMID: 21741597

News

23-Jul-2026
Press Release

J. Craig Venter Institute awarded $200,000 St. Baldrick’s Foundation grant to advance childhood leukemia treatment

Grant will support novel dual-action therapy research targeting MLL-rearranged leukemias in children

01-May-2024

Tae Seok Moon, Ph.D. and Nan Zhu, Ph.D. join J. Craig Venter Institute faculty

JCVI continues to actively recruit faculty to expand core research areas, including human health and synthetic biology